<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229059</url>
  </required_header>
  <id_info>
    <org_study_id>FFAIR</org_study_id>
    <nct_id>NCT01229059</nct_id>
  </id_info>
  <brief_title>Free Fatty Acid Induced Insulin Resistance</brief_title>
  <acronym>FFAIR</acronym>
  <official_title>Assessment of the Time Course of Lipid Induced Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore time-dependent effects of lipid infusion an intramyocellular lipid
      metabolites and the induction of impaired insulin signaling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increased availability of free fatty acids impairs glucose disposal in young healthy humans.
      Patients with type 2 diabetes have reduced whole body glucose disposal, increased ectopic
      lipid deposition in skeletal muscle and the liver and impaired mitochondrial function. Recent
      studies suggest that lipid metabolites such as diacylglycerol (DAG), ceramides and long-chain
      acyl-coA represent the active mediators inducing insulin resistance. Possible targets are
      DAG-sensitive Proteinkinase C (PKC θ, PKC ε) which inhibit the insulin signaling cascade and
      ceramides which interfere with the insulin signaling cascade at Proteinkinase B/AKT. Prior
      studies raised controvesial evidence, thus, it is yet unclear, whether DAG or ceramides are
      the primary agents inducig lipid-induced insulin resistance. Therefore, the current study
      aims to explore the time course of the appearance of intramyocellular lipid compunds during
      lipid infusion in parallel assessing markers of impaired insulin action.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>intramyocellular lipid metabolites</measure>
    <time_frame>after 4 hours lipid infusion</time_frame>
    <description>Muscle biopsies are taken before, after 2.5 and 4 hours of lipid infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle glucose flux</measure>
    <time_frame>during lipid infusion</time_frame>
    <description>glycogen synthesis rate, glucose-6-phosphate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin resistance of glucose uptake and mitochondrial function</measure>
    <time_frame>after 4 hours lipid infusion</time_frame>
    <description>Mitochondrial function will bes assessed from muscle biopsy samples taken after 4 hours, insulin sensitivity will be assessed from hyperinsulinemic-euglycemic clamps following 4 hours lipid infusion</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>lipid infusion in untrained humans</arm_group_label>
    <description>healthy lean humans before and after lipid infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lipid infusion in athletes</arm_group_label>
    <description>endurance trained atheletes</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lipovenös lipid infusion</intervention_name>
    <description>Lipid enriched infusions will be applied for 2-6 hours.</description>
    <arm_group_label>lipid infusion in athletes</arm_group_label>
    <arm_group_label>lipid infusion in untrained humans</arm_group_label>
    <other_name>soy oil</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      muscle biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy, lean non-diabetic humans
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-diabetic (OGTT), no family history of diabetes, BMI&lt;30 kg/m2, age: 20-55 years, no
             medication

        For the athletes group additionally:

          -  VO2max &gt; 60ml/kg/min for males and VO2max &gt; 45ml/kg/min for females Active in
             endurance-exercise activities, 3 times a week for at least 2 years Stable level of
             training for at least 3 months

        Exclusion Criteria:

          -  acute illness within the last 2 weeks, autoimmune diseases, renal insufficiency
             (creatinine&gt; 1.5 mg/dl), cardiovascular diseases, anemia (Hb&lt; 12g/l), donation of
             blood within the last 4 weeks before the study, thyroid diseases, pregnancy, smoking,
             night-shift working (disturbed circadian rhythm), defective coagulation or wound
             healing, cancer, allergy against soja products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Duesseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>November 4, 2018</last_update_submitted>
  <last_update_submitted_qc>November 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendrödi</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>FFA</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>mitochondria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

